Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Angina pectoris

Angina pectoris

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for Angina pectoris

18 trials tracked for Angina pectoris: 5 in phase 3 or 4 and 1 with published results. The most-cited published study has 118 citations.

18Trials tracked
5Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 4 3 Phase 3 2 Phase 2 1 Phase 1 1 Other / NA 11
  1. Phase 3 Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI) Completed · 118 cited
  2. Phase 4 Evaluation of Succinate Metoprolol on Heart Rate in the Stable Angina Patients Completed
  3. Phase 4 Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina Completed
  4. Phase 4 Open Label Study To Evaluate The Long-Term Safety Profiles Of Caduet In Japanese Patients Completed
  5. Phase 3 SPECTACL: SPECTroscopic Assessment of Coronary Lipid Completed
  6. Phase 2 PK and Tolerability of IV and Oral CK-1827452 in Patients With Ischemic Cardiomyopathy and Angina Completed
Show 12 more trials
  1. Phase 1 A Study to Assess the Safety, Tolerability, and Effects of MK-0974 (Telcagepant) on Exercise Tolerance in Patients With Stable Angina (MK-0974-014) Completed
  2. N/A Amlodipine/Atorvastatin (Caduet®) Drug Use Investigation (Regulatory Post Marketing Commitment Plan) Completed
  3. N/A XIENCE PRIME SV Everolimus Eluting Coronary Stent Japan Post Marketing Surveillance (XIENCE PRIME SV Japan PMS) Completed
  4. N/A Absorb GT1 Japan PMS Completed
  5. N/A Volatilome and Single-Lead Electrocardiogram Optimize Ischemic Heart Disease Diagnosis Using Machine Learning Models Completed
  6. N/A An Evaluation of Rigid Sternal Fixation in Supporting Bone Healing and Improving Postoperative Recovery Completed
  7. N/A Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions Completed
  8. N/A The Improving ATTENDance to Cardiac Rehabilitation Trial Completed
  9. N/A Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions Completed
  10. N/A Comparing TR Band to Statseal in Conjunction With TR Band Completed
  11. N/A XIENCE Xpedition Everolimus-Eluting Coronary Stent Japan Post Marketing Surveillance (XIENCE Xpedition SV Japan PMS) Completed
  12. N/A PCP Use of a Gene Expression Test (Corus CAD or ASGES) in Coronary Artery Disease Diagnosis Completed

Showing the 18 most-cited and recently-updated of 18 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Calcium channel blockers cause rare pulmonary toxicity at standard doses but increase risk during overdose
Drug Pipeline Sys. Review
Calcium channel blockers cause rare pulmonary toxicity at standard doses but increase risk during overdose Calcium Channel Blockers Linked to Rare Lung Issues in Overdose
This systematic review examines the incidence and mechanisms of pulmonary toxicity associated with calcium channel blockers (CCBs). While pu…
While calcium channel blockers are generally well-tolerated, some reports link specific types to rare cases of lung fluid buildup.
Frontiers Sep 22, 2026